Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus KETOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus KETOPROFEN.
DYLOJECT vs KETOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Clinical Note
moderateKetoprofen + Gatifloxacin
"Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateKetoprofen + Rosoxacin
"Ketoprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateKetoprofen + Levofloxacin
"Ketoprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateKetoprofen + Trovafloxacin
"Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Category C
Category D/X
NSAID
NSAID